Attenuated Mycobacterium tuberculosis Vaccine Protection in a Low Dose Murine Challenge Model
S. J. Vidal, D. Sellers, J. Yu, S. Wakabayashi, J. Sixsmith, M. Aid, J. Barrett, S. F. Stevens, X. Liu, W. Li, C. R. Plumlee, K. B. Urdahl, A. J. Martinot, D. H. Barouch
This study shows that the live attenuated Mtb vaccine candidate ΔLprG provides better protection than BCG in a low dose murine challenge model, reducing detectable infection and containing it anatomically.
bioRxiv · Mar 17, 2023 · PreprintMicrobiology